19 December 2012 - Leuven, Belgium – TiGenix NV (Euronext Brussels: TIG) today announced that it will launch a private placement of up to 8,629,385 new ordinary shares.
TiGenix will use the funds mainly for the commercial roll out of ChondroCelect in selected European markets and for progressing with the clinical development of Cx601 in complex perianal fistulas in Crohn's patients.The new shares will be placed through an accelerated bookbuilding procedure. The placing will start on 19 December 2012. The Company has asked the Financial Services and Markets Authority (FSMA) to suspend its shares from trading on NYSE Euronext Brussels. Trading in the share will resume shortly following the publication of the results of the placing.
The Company will announce the results of the placing as soon as possible after closing of the bookbuilding.
Source : tigenix.com
This comment has been removed by a blog administrator.
ReplyDelete